Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-13C]pyruvate and 13C magnetic resonance spectroscopic imaging

Magnetic Resonance in Medicine

Volumn 65, Issue 2, 2011, Pages 557-563

  Day, Sam E ^a,c   Kettunen, Mikko I ^b,c   Cherukuri, Murali Krishna ^d   Mitchell, James B ^d   Lizak, Martin J ^a   Morris, H Douglas ^a   Matsumoto, Shingo ^d   Koretsky, Alan P ^a   Brindle, Kevin M ^b,c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

glioma; pyruvate; radiotherapy

Indexed keywords

BLOOD; BLOOD VESSELS; CHEMICAL DETECTION; CHEMICAL SHIFT; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; RADIOTHERAPY; SPIN POLARIZATION;

BACKGROUND SIGNALS; GLIOMA; HYPERPOLARIZED [1; INTRAVENOUS INJECTIONS; MAGNETIC RESONANCE SPECTROSCOPIC IMAGING; PYRUVATES; TREATMENT RESPONSE; WHOLE-BRAIN IRRADIATION;

TUMORS;

CARBON 13; FLUORODEOXYGLUCOSE F 18; LACTIC ACID; PYRUVATE 1 C 13; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN BLOOD VESSEL; BRAIN RADIATION; BRAIN TISSUE; CANCER RADIOTHERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; GLIOMA; HYPERPOLARIZATION; LACTATE BLOOD LEVEL; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; RAT; TISSUE LEVEL; TREATMENT RESPONSE;

EID: 79251566788     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.22698     Document Type: Article

References (23)

1. Brindle K,. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008; 8: 94-107.
2. 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 2008; 29: 1176-1182.
3. 18F-FDG PET in brain tumors. Nucl Med Biol 2009; 36: 779-787.
4. Herholz K, Heindel W, Luyten PR, denHollander JA, Pietrzyk U, Voges J, Kugel H, Friedmann G, Heiss WD,. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992; 31: 319-327.
5. Terpstra M, Gruetter R, High WB, Mescher M, DelaBarre L, Merkle H, Garwood M,. Lactate turnover in rat glioma measured by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 1998; 58: 5083-5088.
6. Martinez-Bisbal MC, Celda B,. Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging 2009; 53: 618-630.
7. McKnight TR,. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol 2004; 31: 605-617.
8. Sibtain NA, Howe FA, Saunders DE,. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62: 109-119.
9. 13C magnetic resonance imaging and spectroscopy. Nat Med 2007; 13: 1382-1387.
10. 13C]pyruvate and [1-13C]lactate in a murine lymphoma. Magn Reson Med 2010; 63: 872-880.
11. 13C-labeled pyruvate utilization as methods for detecting tumor response to treatment. Neoplasia 2009; 11: 574-582, 571.
12. Mispelter J, Lupu M, Briguet A,. NMR probeheads for biophysical and biomedical experiments.Theoretical Principles and Practical Guidelines. London: Imperial College Press; 2006.
13. De Graaf RA,. In vivo NMR spectroscopy: principles and techniques. New Jersey: Wiley; 2007.
14. 13C magnetic resonance metabolic imaging: application to brain tumors. Neuro Oncol 2010; 12: 133-144.
15. Auer RN, Del Maestro RF, Anderson R,. A simple and reproducible experimental in vivo glioma model. Can J Neurol Sci 1981; 8: 325-331.
16. Whittle IR, Macarthur DC, Malcolm GP, Li M, Washington K, Ironside JW,. Can experimental models of rodent implantation glioma be improved? A study of pure and mixed glioma cell line tumours. J Neurooncol 1998; 36: 231-242.
17. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, van Es CA, van den Bent MJ,. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008; 113: 405-410.
18. 13C] ethyl pyruvate. Magn Reson Med 2010; 63: 1137-1143.
19. 13C1-pyruvate. Magn Reson Med 2009; 62: 557-564.
20. 13C metabolic mapping using hyperpolarized 13C-pyruvate. Magn Reson Med 2009; 62: 1-10.
21. Cao Y, Tsien CI, Nagesh V, Junck L, Ten Haken R, Ross BD, Chenevert TL, Lawrence TS,. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006; 64: 876-885.
22. Tarnawski R, Sokol M, Pieniazek P, Maciejewski B, Walecki J, Miszczyk L, Krupska T,. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 2002; 52: 1271-1276.
23. Tomoi M, Kimura H, Yoshida M, Itoh S, Kawamura Y, Hayashi N, Yamamoto K, Kubota T, Ishii Y,. Alterations of lactate (+lipid) concentration in brain tumors with in vivo hydrogen magnetic resonance spectroscopy during radiotherapy. Invest Radiol 1997; 32: 288-296.